This month's dividend screen highlights a new name amid volatility, focusing on safety, growth, and consistency. Check out ...

CrowdStrike is riding the multi-year AI boom, with strong revenue growth, rising TAM, high module adoption. Check out why ...

In the long run, onshoring of drug manufacturing in the US might limit WuXi's growth potential for the long run. Read why ...

Medical Properties Trust delivered stable Q1 earnings, maintains a 1.75x dividend coverage, and has a 37% discount to book.

VWOB is an emerging market debt index ETF. Click here to read more about VWOB ETF and why it is rated as a Buy.

Booz Allen offers AI and cybersecurity solutions with strong financials, growing contracts, and strategic partnerships. Read ...

Alibaba leads in AI adoption and merchant productivity enhancements. Click here to read why BABA stock is upgraded to Buy.

Terna is accelerating its CapEx, notably on €23B 2024–2028 industrial plan. Read why I believe a more appropriate rating is ...

Engie will no longer be exposed to nuclear waste management costs. Read why ENGIY stock offers a compelling investment case.

I now believe that HighPeak can deliver slightly above the high-end of its full-year guidance for production. Read why HPK ...

UnitedHealth Group faces real PBM reform risks, but legal paths, financials, and market pricing suggest opportunity in ...

PFO offers little compensation for its higher leverage and risk profile. Read why I see no compelling reason to prefer PFO ...